Anteris Technologies Global Corp. (AVR) Form 10-Q — Aug 11, 2026
Anteris Technologies Global Corp. reported Q2 2026 net sales of $1.0 million (up 63% year-over-year) and a net loss of $28.8 million versus $21.1 million a year earlier, with first-half losses reaching $51.7 million as R&D spending rose 24% to $40.8 million to fund the PARADIGM pivotal trial and manufacturing scale-up. The balance sheet was transformed by January 2026 raises — a $230.0 million public offering at $5.75 per share plus a $90.0 million Medtronic private placement — leaving $260.9 million in cash, equivalents and restricted cash, supplemented by a new $250.0 million at-the-market program with TD Cowen.
Key figures
- Revenue
- 1503000
- Revenue Yoy
- 28%
- Cash Position
- 260894000
- Shares Outstanding
- 97458474
- Q2 net sales
- 1009000
- H1 2026 rd expense
- 40826000
- Q2 revenue yoy pct
- 63
- Accumulated deficit
- 422650000
- Atm program capacity
- 250000000
- Share price at june 30 2026
- 9.85
- Jan2026 public offering gross proceeds
- 230000000
- Future lease payments not yet commenced
- 23200000
- Jan2026 medtronic private placement gross proceeds
- 90000000
Price after filing
Close on the filing date to close N calendar days later (from $8.91). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.